Naxitamab with novel scheduling and stepped‐up dosing of GM ‐ CSF plus vaccine, but no myeloablative therapy for patients with high‐risk neuroblastoma in first complete remission

Documenti analoghi

• A phase II trial of naxitamab plus stepped‐up dosing of GM ‐ CSF for patients with high‐risk neuroblastoma in second or later complete remission
  di: Brian H. Kushner, et al.
  Pubblicazione: (2026)
• Rapid COJEC without myeloablative therapy for high‐risk neuroblastoma
  di: Brian H. Kushner, et al.
  Pubblicazione: (2025)
• Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti‐GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma
  di: Wei Wei, et al.
  Pubblicazione: (2025)
• Pulmonary hypertension during high‐dose GM‐CSF therapy of autoimmune pulmonary alveolar proteinosis
  di: Ali Ataya, et al.
  Pubblicazione: (2024)
• Irradiated Liver Cancer Cell Vaccine Transfected With GM ‐ CSF Induces Specific and Long‐Lasting Anti‐tumour Immunity Through the Synergistic Effect of Oxidised mtDNA and GM ‐ CSF
  di: Zhiruo Song, et al.
  Pubblicazione: (2026)